Kurzfassung

A phase 2, randomized, double-blind, multicenter, dose-ranging, crossover study to evaluate the safety and efficacy of subcutaneous administration of Cinryze (c1 esterase inhibitor[human] with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in adolsecents and adults with hereditary angioedema